PMID- 33241018
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 18
DP  - 2020 Sep
TI  - Association between IDO activity and prognosis in patients with non-small cell 
      lung cancer after radiotherapy.
PG  - 1169
LID - 10.21037/atm-20-5634 [doi]
LID - 1169
AB  - BACKGROUND: Indoleamine 2,3-dioxygenase (IDO), a limiting enzyme in the 
      IDO/kynurenine (Kyn) pathway, converts tryptophan (Trp) into Kyn, and plays a 
      significant role in immune suppression and tumor immune evasion. This study aimed 
      to investigate the association between IDO activity and clinical outcomes in 
      non-small cell lung cancer (NSCLC) patients who underwent radiotherapy (RT). 
      METHODS: Serum Kyn and Trp levels were measured in 104 NSCLC patients by 
      high-performance liquid chromatography at baseline, and the following RT. The 
      correlation between IDO activity, as computed by Kyn: Trp ratios and survival was 
      estimated using Kaplan-Meier curves. Cox proportional hazard models are used in 
      the univariate and multivariate analyses. RESULTS: Both the Kyn levels and 
      Kyn:Trp ratios were reduced after RT at a biologically equivalent dose (BED) of 
      <70 Gy, while these increased at a BED of >/=70 Gy. Post/pre-Kyn levels were 
      positively correlated with an objective response. Patients with a higher Kyn:Trp 
      ratio pre-RT had the worse median progression-free survival (mPFS, 13.5 vs. 24.5 
      months, P=0.049). Higher post/pre-Kyn:Trp ratios were correlated with improved 
      median overall survival (mOS, 23.8 months vs. not reached, P=0.032). On the 
      multivariate analysis, pre-RT Kyn:Trp and post/pre-Kyn:Trp ratios remained as 
      independent predictive factors for PFS and OS, respectively. CONCLUSIONS: It was 
      proved that RT could alter IDO-mediated immune activity and establish strong 
      correlations between IDO activity and survival outcomes in NSCLC patients treated 
      with RT. These present findings suggest that the profiling of IDO activity might 
      allow for the prompt adjustment of RT doses and better predict patient response 
      to RT.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Zhu, Yaoyao
AU  - Zhu Y
AD  - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - First Clinical Medical School, Wenzhou Medical University, Wenzhou, China.
FAU - Jiang, Chenxue
AU  - Jiang C
AD  - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Liu, Yuanjun
AU  - Liu Y
AD  - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - First Clinical Medical School, Wenzhou Medical University, Wenzhou, China.
FAU - Li, Yefei
AU  - Li Y
AD  - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
FAU - Wu, He
AU  - Wu H
AD  - First Clinical Medical School, Wenzhou Medical University, Wenzhou, China.
FAU - Feng, Jianguo
AU  - Feng J
AD  - Laboratory Research Centre, Cancer Hospital of University of Chinese Academy of 
      Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
FAU - Xu, Yaping
AU  - Xu Y
AD  - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - First Clinical Medical School, Wenzhou Medical University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7576049
OTO - NOTNLM
OT  - Indoleamine 2,3-dioxygenase activity (IDO activity)
OT  - non-small cell lung cancer (NSCLC)
OT  - prognosis
OT  - radiotherapy-induced immune response
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-5634). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
PMCR- 2020/09/01
CRDT- 2020/11/26 05:48
PHST- 2020/11/26 05:48 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - atm-08-18-1169 [pii]
AID - 10.21037/atm-20-5634 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Sep;8(18):1169. doi: 10.21037/atm-20-5634.